{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T09:10:51Z","timestamp":1765530651522,"version":"3.48.0"},"reference-count":14,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>Rapid methadone metabolism in patients with opioid use disorder could complicate methadone treatment. Toxicology screenings to monitor methadone levels may show negative for methadone, even with regular adherence to a regimen. A patient receiving treatment for opioid use disorder tested negative for methadone in 11 out of 22 toxicology screenings (50.0%). We hypothesized that the patient was a rapid methadone metabolizer. After tapering doses to a maintenance level and using supervised urine collection, the patient was negative for methadone in seven out of seven tests (100.0%), but positive for cocaine in five out of seven tests (71.4%) near the end of the maintenance period. Chronic cocaine use and genetic factors, particularly CYP2B6 polymorphisms, have been found to cause rapid methadone metabolism. Clinicians should be vigilant for unusual metabolic reactions and modify dose and monitoring schedules accordingly. More investigation into the physiological and genetic aspects of methadone metabolism is needed.<\/jats:p>","DOI":"10.3390\/reports8040262","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T08:30:17Z","timestamp":1765528217000},"page":"262","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Rapid Methadone Metabolism in Opioid Use Disorder: A Case Report of Clinical Challenges and Individualized Treatment Approaches"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8157-6413","authenticated-orcid":false,"given":"Farhana","family":"Nazmin","sequence":"first","affiliation":[{"name":"Psychiatry, Bronxcare Health System, Bronx, New York, NY 10456, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2465-8730","authenticated-orcid":false,"given":"Jaskaran","family":"Singh","sequence":"additional","affiliation":[{"name":"Psychiatry and Behavioural Sciences, Nassau University Medical Center, East Meadow, New York, NY 10456, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8318-6409","authenticated-orcid":false,"given":"Narges","family":"Joshaghani","sequence":"additional","affiliation":[{"name":"Psychiatry, Bronxcare Health System, Bronx, New York, NY 10456, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisio","family":"Go","sequence":"additional","affiliation":[{"name":"Psychiatry, Bronxcare Health System, Bronx, New York, NY 10456, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2009, November 01). Regional Office for the Western Pacific, Clinical Guidelines for Withdrawal Management and Treatment of Drug Dependence in Closed Settings, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK310654\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cpr.2009.10.006","article-title":"A review of opioid dependence treatment: Pharmacological and psychosocial interventions to treat opioid addiction","volume":"30","author":"Veilleux","year":"2010","journal-title":"Clin. Psychol. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1176\/appi.ps.201300249","article-title":"Substance Abuse Intensive Outpatient Programs: Assessing the Evidence","volume":"65","author":"McCarty","year":"2014","journal-title":"Psychiatr. Serv."},{"key":"ref_4","first-page":"73","article-title":"Pharmacogenomic considerations in opioid analgesia","volume":"5","author":"Landau","year":"2012","journal-title":"Pharmgenom. Pers. Med."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Strain, E. (2005). The Treatment of Opioid Dependence, Johns Hopkins University Press.","DOI":"10.56021\/9780801882197"},{"key":"ref_6","unstructured":"SAMHSA (2006). TIP 63: Medications for Opioid Use Disorder, SAMHSA."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00003088-200241140-00003","article-title":"Interindividual Variability of the Clinical Pharmacokinetics of Methadone","volume":"41","author":"Eap","year":"2002","journal-title":"Clin. Pharmacokinet."},{"key":"ref_8","unstructured":"Leavitt (2009). TIP 63: Medications for Opioid Use Disorder, Leavitt."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.drugalcdep.2005.06.005","article-title":"Therapeutic thresholds in methadone maintenance treatment: A receiver operating characteristic analysis","volume":"81","author":"Hallinan","year":"2006","journal-title":"Drug Alcohol. Depend."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3109\/10884601003628112","article-title":"Case Report","volume":"21","author":"Hobbins","year":"2010","journal-title":"J. Addict. Nurs."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.soncn.2009.03.012","article-title":"Understanding the Genetic Determinants of Pain and Pain Management","volume":"25","author":"Miaskowski","year":"2009","journal-title":"Semin. Oncol. Nurs."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/FPC.0b013e32835cb2e2","article-title":"Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels","volume":"23","author":"Dobrinas","year":"2013","journal-title":"Pharmacogenet. Genom."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/j.1521-0391.2009.00009.x","article-title":"Effect of Cocaine Use on Methadone Pharmacokinetics in Humans","volume":"19","author":"Jatlow","year":"2010","journal-title":"Am. J. Addict."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Talal, A.H., Ding, Y., Venuto, C.S., Chakan, L.M., McLeod, A., Dharia, A., Morse, G.D., Brown, L.S., Markatou, M., and Kharasch, E.D. (2020). Toward precision prescribing for Methadone: Determinants of methadone deposition. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0231467"}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/4\/262\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T09:05:58Z","timestamp":1765530358000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/8\/4\/262"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["reports8040262"],"URL":"https:\/\/doi.org\/10.3390\/reports8040262","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,12]]}}}